Evaluation of the effects of Pilocarpine gum on saliva secretio
Phase 2
- Conditions
- Dry mouth caused by Sjogren's syndrome.Sicca syndrome [Sjogren]M35.0
- Registration Number
- IRCT20191106045356N19
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Willingness to participate in the study and complete the ethical consent form
Patients with Sjogren's syndrome under standard treatment
Exclusion Criteria
Irritation or allergic reaction to the drug
Absence of specific systemic disease
Absence of sores and inflammation or infection in the mouth and throat
Not taking Pilocarpine or Cevimeline in the week before the test
No glaucoma
No respiratory disease such as asthma
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The amount of saliva secretion. Timepoint: Measuring the volume of saliva secreted at the beginning of the study (before the start of the intervention) and after taking the first dose on the first day and the last dose on the third day. Method of measurement: Changing the weight of the dental cotton roll by absorbing the saliva secreted in the mouth.
- Secondary Outcome Measures
Name Time Method